VII

R4 Capital Closes 2022 Exceeding $8 Billion

Retrieved on: 
Thursday, March 2, 2023
Finance, Professional Services, Residential Building & Real Estate, Asset Management, Construction & Property, XIX, IRR, VII, Partner, Housing, XVIII, XVII, DC, Security (finance), Renewable energy, LIHTC, R4

R4 Capital , a national affordable housing tax-credit syndicator, loan servicer, and asset manager, and R4 Capital Funding , R4’s tax-exempt lending subsidiary, announced that the firm has closed more than $8 billion in tax credit equity investments and tax-exempt mortgage capital on behalf of its more than 110 institutional investors in 12 years.

Key Points: 
  • R4 Capital , a national affordable housing tax-credit syndicator, loan servicer, and asset manager, and R4 Capital Funding , R4’s tax-exempt lending subsidiary, announced that the firm has closed more than $8 billion in tax credit equity investments and tax-exempt mortgage capital on behalf of its more than 110 institutional investors in 12 years.
  • In 2022, R4 and R4CF closed more than $1.4 billion in LIHTC equity and tax-exempt debt.
  • At the end of 2022, R4 closed $755 million of LIHTC equity, with $690 million closed into multi-investor funds and $65 million of proprietary investments.
  • R4’s 2022 multi-investor funds included:
    $319 million in R4 Housing Partners XVIII LP, a national equity fund.

Pro-Tech Group Receives Patent for Bi-Directional Loader for Handling Cargo

Retrieved on: 
Wednesday, February 8, 2023
Shoulder, Mechanics, Patent, Construction, PTC, United States Patent and Trademark Office, Injury, Safety, National Association, Ford Motor Company, Engineering, VII, U.S. Department of Commerce Office of Security, Canadian National Railway, Partnership, Death, OSHA, Hydraulic machinery, Fine chemical, Heavy equipment, 3D printing, Roush

Pro-Tech Group chose Roush Industries Inc. to complete a feasibility study and build a working prototype for pilot testing in Q4 2023.

Key Points: 
  • Pro-Tech Group chose Roush Industries Inc. to complete a feasibility study and build a working prototype for pilot testing in Q4 2023.
  • Safety and speed are at the forefront of our decision to pursue this innovation further," says Earle B. Higgins, CEO of Pro-Tech Group.
  • Our bi-directional loader will improve worksite safety and the speed of handling cargo and other items."
  • Pro-Tech Group estimates a decrease in PTC handling time of up to 50% by substituting today's standard telescopic loader with the bi-directional loader.

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Retrieved on: 
Tuesday, February 7, 2023
AACR, Concha bullosa, VII, Cancer, PLK1, Rigosertib, Risk, Conference, Patient, Skin, FDA, SCC, Neoplasm, Radiation, Death, Infection, Thomas Jefferson University, Therapy, American Association for Cancer Research, Pharmaceutical industry, RDEB

NEWTOWN, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the second of two evaluable participants in an investigator-initiated Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib.

Key Points: 
  • The Company previously announced that the RDEB-associated SCC program’s first evaluable participant achieved a RECIST-defined complete response.
  • Both of the program’s evaluable participants remain on therapy, with the first participant in complete remission with no signs of metastatic disease for more than 18 months.
  • Rigosertib continues to demonstrate a favorable safety profile in this indication that is similar to that displayed in prior studies in other indications.
  • In addition, these findings may have important implications beyond this orphan indication, as they and prior preclinical data demonstrate rigosertib’s activity against the PLK1 protein.

Rosca Scarlato, LLC Announces Proposed Class Action Settlement on Behalf of Purchasers of Vida Longevity Fund, LP limited partnership interests

Retrieved on: 
Monday, January 30, 2023
Telephone, Lawyer, Indian Residential Schools Settlement Agreement, Prejudice, VII, Action, Hearing, Notice, Court, ARE, Suite, Class, Claim, United States Senate Judiciary Subcommittee on Federal Courts, Oversight, Agency Action and Federal Rights, Defendant, Partnership, Person, District court, Federal Rules of Civil Procedure, Settlement, Magistrate, Tobacco, Insurance, Allocation, Media, LP

YOU ARE ALSO NOTIFIED that the Plaintiffs have reached a proposed settlement of the Action for $1,400,000 in cash (the “Settlement”), which, if approved, will resolve all claims in the Action.

Key Points: 
  • YOU ARE ALSO NOTIFIED that the Plaintiffs have reached a proposed settlement of the Action for $1,400,000 in cash (the “Settlement”), which, if approved, will resolve all claims in the Action.
  • If the hearing is held by telephone or videoconference, information on how to participate will be posted at www.strategicclaims.net/VLF .
  • If you are a Class Member, your rights will be affected by the pending Action and the Settlement, and you might be entitled to a payment from the Settlement.
  • You also can file claims online or download copies of the Notice and Claim Form from the Settlement website, www.strategicclaims.net/VLF .

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Wednesday, January 25, 2023
RNA, Alport syndrome, Safety, Patient, Proteinuria, VII, Mutation, COL4, COL, Cell, Degenerative disease, Pharmaceutical industry, Alport

WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.

Key Points: 
  • WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.
  • “With enrollment of the first patients in our Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations, we remain on track to deliver topline clinical results from this trial in the first half of 2023,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • “ELX-02 treatment has demonstrated restoration of full-length protein in multiple preclinical models, including collagen IV and collagen VII in cells, and also clinical activity in our Phase 2 cystic fibrosis trial.
  • For eligible patients, induction of COL IV will also be measured at the end of two months.

Banzai Announces Launch of Boost, to Increase Registrations for Webinars and Other Live and Automated Video Content

Retrieved on: 
Thursday, January 12, 2023
Marketing, Digital Marketing, Communications, Technology, Audio, Video, Software, Internet, Social media, VII, B2B, Associated Press v. Meltwater U.S. Holdings, Inc., Friends, International, Mazda Demio, Reward, Marketing, Growth, Acquisition, Video game, Boost

Banzai International, Inc. (“Banzai” or the “Company”), a leading end-to-end video engagement platform for marketing, announced today the launch of Boost , a new product offering that enables marketers to increase registrations for virtual live and automated webinars and events.

Key Points: 
  • Banzai International, Inc. (“Banzai” or the “Company”), a leading end-to-end video engagement platform for marketing, announced today the launch of Boost , a new product offering that enables marketers to increase registrations for virtual live and automated webinars and events.
  • Increasing registration and attendance is a top priority for marketers who manage webinars and other video content.
  • Boost is an add-on to Banzai’s engagement marketing platform Demio , a solution built for marketers that want to drive results with live and automated, no-download video marketing content such as webinars and virtual events.
  • “Boost helps solve a key problem in the marketing industry, which is driving registrations for live and automated webinars and events.

EQS-News: Deutsche Beteiligungs AG: Successful realisation of investment in Pmflex

Retrieved on: 
Sunday, January 22, 2023
Software, Calendar, Automation, Robotics, News, DBAG, Hager Group, Growth, MBO, VII, Telecommunication, DACH, Sale, Security (finance), Renewable energy

DBAG Fund VII and Deutsche Beteiligungs AG (“DBAG”) have successfully concluded their investment in Pmflex (formerly: PM Plastic Materials), a leading European manufacturer of electrical installation conduits.

Key Points: 
  • DBAG Fund VII and Deutsche Beteiligungs AG (“DBAG”) have successfully concluded their investment in Pmflex (formerly: PM Plastic Materials), a leading European manufacturer of electrical installation conduits.
  • DBAG and DBAG Fund VII acquired a majority stake in Pmflex from the company’s founding family in September 2020, structuring DBAG’s first management buyout (MBO) in Italy.
  • DBAG Fund VII’s total investment in Pmflex amounted to approximately 73 million euros, of which DBAG contributed around 11 million euros.
  • With the sale of the Pmflex investment, DBAG Fund VII has achieved the third disposal of a management buyout (MBO) from its portfolio.

7GC & Co. Holdings Inc. Announces Postponement of its Special Meeting of Stockholders to December 21, 2022 and That Trust Account Will Bear Interest and Will Not Be Decreased Due to Excise Tax

Retrieved on: 
Monday, December 19, 2022
Interest on Lawyer Trust Accounts, Calendar, Date, Proxy statement, Meeting, Proxy, Bank account, Inflation, SAN, Extension, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., The Meeting, Sponsor, VII, Business architecture, Holding company

The record date for determining the Company stockholders entitled to receive notice of and to vote at the Meeting remains the close of business on November 21, 2022 (the “Record Date”).

Key Points: 
  • The record date for determining the Company stockholders entitled to receive notice of and to vote at the Meeting remains the close of business on November 21, 2022 (the “Record Date”).
  • Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not take any action.
  • Stockholders as of the Record Date can vote, even if they have subsequently sold their shares.
  • Additionally, if the Extension is implemented, the Company plans to maintain the remaining amount in its trust account (the “Trust Account”) in an interest-bearing demand deposit account at a bank.

Panasonic Automotive Updates SkipGen In-Vehicle Infotainment System to Offer Industry-First Wake Word Access to Siri and Alexa

Retrieved on: 
Tuesday, January 10, 2023
Alexa, Navigation, IPhone, Human voice, CES, Amazon Alexa, Panasonic, Weather, Siri, SDK, Automotive industry, IVI, Internet, VII, Human, AIS, Intelligence, Mobile phone, Satellite navigation device, Online shopping, CarPlay, Amazon
Key Points: 
  • On SkipGen, some customers may want to use Siri for iPhone features in Apple CarPlay, or Alexa for in-vehicle controls and more.
  • This increases customer value by providing simultaneous access to Siri and Alexa with their corresponding capabilities on a single system through the wake words.
  • That is why Amazon and Panasonic Automotive have collaborated to develop this integration for SkipGen, which is enabled by the Alexa Auto SDK, and relies on Panasonic's deep experience integrating Siri and CarPlay into automotive systems.
  • In addition to the benefits of the multi-assistant integration, the Alexa Auto SDK provides core Alexa functionality, such as wake word detection, speech recognition, and synthesis.

Dystrophic Epidermolysis Bullosa Drug Pipeline Analysis Report 2022: Comprehensive Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Other Health, Epidermolysis bullosa dystrophica, VII, II, Patient, RDEB, Tissue, Shire (pharmaceutical company), Disease, III, Concha bullosa, Discovery, Clinical trial, News, COL7, Wound healing, Therapy, NDA, Survival, DEB, Skin, Research, Tooth discoloration, Acquisition, Medical device, Medical imaging, Pharmaceutical industry

This report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape.
  • The assessment part of the report embraces, in depth Dystrophic Epidermolysis Bullosa commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the Dystrophic Epidermolysis Bullosa report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Dystrophic Epidermolysis Bullosa) includes therapeutic assessment and comparative analysis.